Lixte Biotechnology Holdings Inc.(LIXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LIXT Lixte Biotechnology Holdings Inc.

Trading 06-08 13:57:28 EDT

6.35

-0.65

-9.29%

High7.36	Low6.30	Vol166.62K
Open7.24	D1 Closing7.00	Amplitude15.14%
Mkt Cap97.02M	Tradable Cap11.52M	Total Shares15.28M
T/O1.14M	T/O Rate9.19%	Tradable Shares1.81M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LIXT","market":"US","secType":"STK","nameCN":"Lixte Biotechnology Holdings Inc.","latestPrice":6.35,"timestamp":1780941423255,"preClose":7,"halted":0,"volume":166620,"delay":0,"changeRate":-0.0928571428571429,"floatShares":1813503,"shares":15278806,"eps":-1.15,"marketStatus":"Trading","change":-0.65,"latestTime":"06-08 13:57:28 EDT","open":7.24,"high":7.36,"low":6.3,"amount":1142181.699552,"amplitude":0.151429,"askPrice":6.59,"askSize":100,"bidPrice":6.3,"bidSize":920,"shortable":0,"etf":0,"ttmEps":-1.15,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1780948800000},"marketStatusCode":2,"adr":0,"listingDate":1606280400000,"exchange":"NASDAQ","adjPreClose":7,"preHourTrading":{"tag":"盘前","latestPrice":6.85,"preClose":7,"latestTime":"06:33 EDT","volume":3,"amount":21.5500002,"timestamp":1780914784319,"change":-0.15,"changeRate":-0.021429,"amplitude":0.071429},"postHourTrading":{"tag":"盘后","latestPrice":6.72,"preClose":7,"latestTime":"17:54 EDT","volume":3857,"amount":25921.8335,"timestamp":1780696445346,"change":-0.28,"changeRate":-0.04,"amplitude":0.04},"volumeRatio":0.713637},"requestUrl":"/m/hq/s/LIXT","defaultTab":"news","newsList":[{"id":"2641107198","title":"Lixte Biotechnology Announces At-the-Market Equity Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2641107198","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641107198?lang=en_us&edition=fundamental","pubTime":"2026-06-05 07:07","pubTimestamp":1780614450,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings ( ($LIXT) ) just unveiled an announcement. On June 2, 2026, Lixte Biotechnology Holdings, Inc. entered into a securiti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lixte-biotechnology-announces-at-the-market-equity-financing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lixte-biotechnology-announces-at-the-market-equity-financing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","BK4215","LIXT","EQR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640027839","title":"Lixte Biotechnology Prices $16.6 Million Registered Direct Offering Priced at the Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2640027839","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640027839?lang=en_us&edition=fundamental","pubTime":"2026-06-03 21:19","pubTimestamp":1780492768,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology  has agreed with accredited investors for a registered direct offering of $16.6 million of shares and pre-funded warrants, the company said Wednesday.The offering includes 2.63 million common shares and pre-funded warrants priced at $6.31 per share, it said.The entire deal was priced at the market, the company said.Lixte said it will use net proceeds, together with existing cash, for general corporate purposes, working capital and strategic initiatives.The deal is expected to close on or about Wednesday.Shares of the company were 3.7% higher in recent Wednesday premarket trading.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LIXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640549904","title":"Lixte Biotechnology prices USD 16.57 million registered direct offering at USD 6.31/share","url":"https://stock-news.laohu8.com/highlight/detail?id=2640549904","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640549904?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:31","pubTimestamp":1780489877,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings launched a registered direct offering targeting USD 16.57 million, priced at-the-market under Nasdaq rules.Deal set at USD 6.31 per common share; includes pre-funded warrants priced at USD 6.3099 with a USD 0.0001 exercise price.Offering covers 2,625,362 shares of common stock plus pre-funded warrants exercisable for one share each.Gross proceeds expected to be about USD 16.57 million; closing expected on or about June 3, 2026.Proceeds earmarked for general corporate purposes, working capital, and strategic initiatives.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief on June 03, 2026, and is solely responsible f","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL52Mcpm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640904371","title":"Lixte Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2640904371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640904371?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:30","pubTimestamp":1780489802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUA8WKKT8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIXT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640964887","title":"Lixte Biotechnology director Stuart D. Porter files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2640964887","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640964887?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:01","pubTimestamp":1780344060,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology filed an initial beneficial ownership statement for director Stuart D. Porter, dated May 29, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL6qQZvp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640952735","title":"Lixte Biotechnology Shifts Strategy to AI Energy Infrastructure","url":"https://stock-news.laohu8.com/highlight/detail?id=2640952735","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640952735?lang=en_us&edition=fundamental","pubTime":"2026-06-01 21:40","pubTimestamp":1780321247,"startTime":"0","endTime":"0","summary":"An update from Lixte Biotechnology Holdings ( ($LIXT) ) is now available. On May 29, 2026, Lixte Biotechnology’s board appointed veteran energy inv...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lixte-biotechnology-shifts-strategy-to-ai-energy-infrastructure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lixte-biotechnology-shifts-strategy-to-ai-energy-infrastructure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIX","BK4139","AIPO","CHAT","ARTY","LIXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640954304","title":"Lixte names Denham Capital founder Stuart Porter to board amid strategic shift","url":"https://stock-news.laohu8.com/highlight/detail?id=2640954304","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640954304?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:50","pubTimestamp":1780318220,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology named Denham Capital founder Stuart D. Porter to its board, effective today.Porter is Denham’s founder, managing partner, CEO, chief investment officer; oversaw more than $12 billion across energy, energy-transition investments.Board addition aligns with Lixte’s shift toward AI power infrastructure equipment and services for data centers.Denham’s infrastructure group is advancing about 10 GW of AI data-center-oriented power generation opportunities in the US and Europe.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDLX0dMJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","BK4139","LU2210150020.SGD","LIXT","BK4112","LU2210149790.SGD","IE00BGHQF748.EUR","BK4585","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4588","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014021.USD","SG9999014005.SGD","LU2095319765.USD","SG9999014039.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640545869","title":"Lixte Biotechnology - Expects to Maintain Nasdaq Listing Under Ticker 'Lixt' During Transformation","url":"https://stock-news.laohu8.com/highlight/detail?id=2640545869","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640545869?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:50","pubTimestamp":1780318200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUA6ZDJHL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIXT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640543779","title":"Lixte Biotechnology - to Seek Strategic Acquisition Partner for Pharmaceutical & Med-Tech Operations Focused on Advancing Cancer Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2640543779","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640543779?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:50","pubTimestamp":1780318200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUA6ZDJHL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIXT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640543369","title":"Lixte Biotechnology Announces Strategic Transformation Into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2640543369","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640543369?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:50","pubTimestamp":1780318200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUA6ZDJHL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIXT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635721988","title":"Lixte Biotechnology Q1 EPS USD -0.18","url":"https://stock-news.laohu8.com/highlight/detail?id=2635721988","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635721988?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:35","pubTimestamp":1778794552,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLX37E5AF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIXT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635572976","title":"Lixte Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635572976","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635572976?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:18","pubTimestamp":1778793480,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA2TJRVQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635726790","title":"Lixte Biotechnology Q1 FY26 net loss widens to $1.99 million; operating loss widens to $1.99 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635726790","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635726790?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:51","pubTimestamp":1778791911,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology posted a net loss of USD 1.99 million for quarter ended March 31, 2026, worsening from USD 709,555 a year earlier; net loss per share narrowed to USD 0.18 from USD 0.29.Operating loss widened to USD 1.99 million from USD 706,940 as total costs and expenses climbed to USD 1.99 million from USD 706,940.Research and development expense rose to USD 333,376 from USD 91,457, while general and administrative expense increased to USD 1.65 million from USD 615,483.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange C","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL5Q3Tvs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630299319","title":"LIXTE Biotechnology Holdings (NASDAQ: LIXT) Unlocking New Potential in Precision Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2630299319","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630299319?lang=en_us&edition=fundamental","pubTime":"2026-04-28 01:30","pubTimestamp":1777311034,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, April 27th, 2026, FinanceWire LIXTE Biotechnology Holdings (NASDAQ:LIXT) is advancing the precision oncology lan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-holdings-nasdaq-lixt-unlocking-new-potential-in-precision-cancer-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-holdings-nasdaq-lixt-unlocking-new-potential-in-precision-cancer-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNQmain","LIXT","QQQJ","QLD","NDX","SQQQ","QYLG","JEPQ","QQQE","BK4139","TQQQ","IYW","FTEC","QQQ","NQmain","ONEQ","QDTE","GPIQ","QQQY","QID","QQQA","NVIW.SI","QQQM","PSQ",".IXIC","TQQY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629029614","title":"Greenland Mines appoints Jason D. Sawyer to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2629029614","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629029614?lang=en_us&edition=fundamental","pubTime":"2026-04-23 01:14","pubTimestamp":1776878060,"startTime":"0","endTime":"0","summary":"Greenland Mines appointed Jason D. Sawyer to board of directors effective April 17, 2026.Sawyer is general manager of Access Alternative Group, a Nassau-based venture investment and advisory firm.He currently serves as CEO and a director of GridAI Technologies.Sawyer also holds board roles at The FUTR Corp., Lixte Biotechnology Holdings, Perpetuals.com.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Greenland Mines Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL8DG90t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIXT","GRML"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629778555","title":"LIXTE Biotechnology Holdings (NASDAQ: LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape","url":"https://stock-news.laohu8.com/highlight/detail?id=2629778555","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629778555?lang=en_us&edition=fundamental","pubTime":"2026-04-21 02:00","pubTimestamp":1776708025,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, April 20th, 2026, FinanceWire Boca Raton, Florida-based LIXTE Biotechnology Holdings (NASDAQ:LIXT) spent 20...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-holdings-nasdaq-lixt-positions-lb-100-as-novel-approach-in-cancer-treatment-landscape?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-holdings-nasdaq-lixt-positions-lb-100-as-novel-approach-in-cancer-treatment-landscape?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QQQE","JEPQ","BK4139","QQQJ","QDTE","QQQ","BK4213","MNQmain",".IXIC","QID","PSQ","QLD","BK4233","TQQQ","IYW","GPIQ","QQQY","QYLG","FTEC","LB","TQQY","LIXT","QQQM","ONEQ","SQQQ","QQQA","NQmain","NDX","NVIW.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628400781","title":"Lixte Biotechnology replaces stock options with RSUs for executives, directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2628400781","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628400781?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:06","pubTimestamp":1776456402,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings swapped previously granted stock options for fully vested restricted share units on April 15, 2026.Chief Executive Officer Geordan Pursglove had 350,000 options cancelled, replaced with 350,000 RSUs.Chief Financial Officer Peter Stazzone had 50,000 options cancelled, replaced with 50,000 RSUs.Directors received replacement awards totaling 100,000 RSUs, matching 100,000 options cancelled.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 17, 2026, and is solely responsible for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL3CCjvf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIXT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627527124","title":"LIXTE Biotechnology (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2627527124","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627527124?lang=en_us&edition=fundamental","pubTime":"2026-04-14 00:30","pubTimestamp":1776097818,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, April 13th, 2026, FinanceWire LIXTE Biotechnology Holdings (NASDAQ:LIXT), a clinical-stage pharmaceutical compan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-nasdaq-lixt-reports-interim-ovarian-cancer-trial-results-at-sgo-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-nasdaq-lixt-reports-interim-ovarian-cancer-trial-results-at-sgo-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QDTE","TQQY","ONEQ","NDX","BK4139","IYW","QQQE",".IXIC","QYLG","PSQ","QQQY","FTEC","SQQQ","QID","LIXT","NQmain","JEPQ","QQQA","QQQJ","QQQM","NVIW.SI","QLD","MNQmain","TQQQ","GPIQ","QQQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627045886","title":"Lixte reports favorable interim results for LB-100 plus dostarlimab ovarian cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627045886","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627045886?lang=en_us&edition=fundamental","pubTime":"2026-04-13 20:06","pubTimestamp":1776081983,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology reported preliminary results already presented at Society of Gynecological Cancer conference held April 10-13, 2026 in San Juan for a trial combining LB-100 with GSK’s PD-1 drug Dostarlimab in ovarian clear cell carcinoma.Interim readout showed an acceptable safety profile and signs of disease control, supporting continued development of combination regimen.Enrollment reached 21 planned participants, with 20 included in interim efficacy analysis.Program is expanding with an additional 21-patient cohort now enrolling at higher LB-100 exposure to further test activity in patients lacking genetic reduction in PP2A.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDLSD8Ml:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014013.SGD","SG9999014039.USD","SG9999014005.SGD","IE00BN0W2W23.USD","SG9999014021.USD","LU2210149790.SGD","IE00BKPKM429.USD","BK4585","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LIXT","BK4588","IE00BGHQF748.EUR","LU2095319765.USD","IE00BN0W2T93.GBP","LU0314104364.USD","NDAQ","BK4139","LU2210150020.SGD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627430432","title":"Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2627430432","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627430432?lang=en_us&edition=fundamental","pubTime":"2026-04-13 20:00","pubTimestamp":1776081604,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nTUA8SS1VZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIXT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lixte.com","stockEarnings":[{"period":"1week","weight":0.12},{"period":"1month","weight":0.5909},{"period":"3month","weight":1.8689},{"period":"6month","weight":0.7284},{"period":"1year","weight":4.0725},{"period":"ytd","weight":0.7812}],"compareEarnings":[{"period":"1week","weight":-0.025},{"period":"1month","weight":0.0051},{"period":"3month","weight":0.0969},{"period":"6month","weight":0.0756},{"period":"1year","weight":0.2437},{"period":"ytd","weight":0.0816}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.153774},{"month":2,"riseRate":0.625,"avgChangeRate":0.06495},{"month":3,"riseRate":0.5,"avgChangeRate":-0.03366},{"month":4,"riseRate":0.375,"avgChangeRate":-0.074412},{"month":5,"riseRate":0.444444,"avgChangeRate":0.082784},{"month":6,"riseRate":0.555556,"avgChangeRate":0.041035},{"month":7,"riseRate":0.625,"avgChangeRate":0.400968},{"month":8,"riseRate":0.5,"avgChangeRate":0.097631},{"month":9,"riseRate":0.375,"avgChangeRate":0.00973},{"month":10,"riseRate":0.375,"avgChangeRate":-0.019298},{"month":11,"riseRate":0.375,"avgChangeRate":-0.035386},{"month":12,"riseRate":0.25,"avgChangeRate":-0.145393}],"exchange":"NASDAQ","name":"Lixte Biotechnology Holdings Inc.","nameEN":"Lixte Biotechnology Holdings Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lixte Biotechnology Holdings Inc.(LIXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lixte Biotechnology Holdings Inc.(LIXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lixte Biotechnology Holdings Inc.,LIXT,Lixte Biotechnology Holdings Inc.股票,Lixte Biotechnology Holdings Inc.股票老虎,Lixte Biotechnology Holdings Inc.股票老虎国际,Lixte Biotechnology Holdings Inc.行情,Lixte Biotechnology Holdings Inc.股票行情,Lixte Biotechnology Holdings Inc.股价,Lixte Biotechnology Holdings Inc.股市,Lixte Biotechnology Holdings Inc.股票价格,Lixte Biotechnology Holdings Inc.股票交易,Lixte Biotechnology Holdings Inc.股票购买,Lixte Biotechnology Holdings Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lixte Biotechnology Holdings Inc.(LIXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lixte Biotechnology Holdings Inc.(LIXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}